Darleukin Completed Phase 2 Trials for Malignant Melanoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01253096Intratumoral Application of L19IL2 in Patients With Malignant Melanoma